2023
Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, Leventhal J, Morford K, Sue K. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. Journal Of Addiction Medicine 2023, 17: 739-741. PMID: 37934550, DOI: 10.1097/adm.0000000000001198.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersDrug useCase report presentsIndex of suspicionInjection drug useDrug supplyCare management strategiesHarm reduction strategiesOverdose presentationsCutaneous manifestationsWithdrawal syndromeClinical complicationsCase reportIntravenous useWound carePatientsTreatment of woundsInfectious diseasesChronic woundsXylazineSkin woundsWoundsMore reportingDiagnosisFacilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial
Muvvala S, Gan G, Morford K, Dziura J, Esserman D, Porter E, Chan P, Cornman D, Reynolds J, Yager J, Fiellin D, Edelman E. Facilitation and Preferred Models for Delivering Substance Use Disorder Treatment in HIV Clinics: Results From a Multisite Randomized Trial. Journal Of Addiction Medicine 2023, 17: e388-e391. PMID: 37934538, PMCID: PMC10726383, DOI: 10.1097/adm.0000000000001192.Peer-Reviewed Original ResearchConceptsOpioid use disorderAlcohol use disorderTobacco use disorderHIV clinicUse disordersAddiction treatmentSubstance use disorder treatmentUse disorder treatmentMaintenance phaseRandomized trialsStaff preferencesImproved outcomesMultisite Randomized TrialImplementation facilitationDisorder treatmentControl phaseClinicCliniciansTreatment modelTreatmentDisordersSignificant differencesInterventionHigher proportionAddiction treatment models
2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersGrief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications
Morford KL, Batchelor HM, Tetrault JM. Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. Journal Of Addiction Medicine 2022, 16: 613-615. PMID: 35165230, DOI: 10.1097/adm.0000000000000976.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid overdose crisisOverdose crisisImmunodeficiency syndrome (AIDS) epidemicCare of peopleTreatment outcomesOverdose deathsUse disordersEmotional burdenSocial support networksContext of stigmaHarmful consequencesSupport networksRole of griefGriefPatientsOverdoseCliniciansEffect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentivesPatients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study
Morford KL, Muvvala SB, Chan PA, Cornman DH, Doernberg M, Porter E, Virata M, Yager JE, Fiellin DA, Edelman EJ. Patients' perspectives of medications for addiction treatment in HIV clinics: A qualitative study. Journal Of Substance Use And Addiction Treatment 2022, 139: 108767. PMID: 35341613, PMCID: PMC9187601, DOI: 10.1016/j.jsat.2022.108767.Peer-Reviewed Original ResearchConceptsSubstance use disordersHIV clinicAddiction treatmentSubstance useEvidence-based medicationsMedication treatment optionsMedication side effectsHealth Services frameworkFocus groupsHIV cliniciansTreatment optionsMultidisciplinary screeningChronic diseasesPatient educationPatient's perspectivePromoting ActionStudy populationDisorder careSide effectsUse disordersPatient receptivityQualitative studyOverall healthClinicKnowledge deficits
2021
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal Of Addiction Medicine 2021, 16: 399-406. PMID: 34954746, DOI: 10.1097/adm.0000000000000945.Peer-Reviewed Original ResearchConceptsLow dose initiationFull opioid agonistsDose initiationOpioid withdrawal symptomsOpioid agonistsBuprenorphine doseWithdrawal symptomsHigh potency synthetic opioidsOpioid use disorderAppropriate clinical situationsMu-opioid receptorsBuprenorphine initiationOpioid withdrawalStarting doseOutpatient settingCare coordinationDose changesOverdose deathsCurrent evidenceUse disordersBuprenorphineTherapeutic levelsClinical situationsSynthetic opioidsNarrative reviewLaw enforcement assisted diversion: Qualitative evaluation of barriers and facilitators of program implementation
Joudrey PJ, Nelson CR, Lawson K, Morford KL, Muley D, Watson C, Okafor M, Wang EA, Crusto C. Law enforcement assisted diversion: Qualitative evaluation of barriers and facilitators of program implementation. Journal Of Substance Use And Addiction Treatment 2021, 129: 108476. PMID: 34080562, PMCID: PMC8380645, DOI: 10.1016/j.jsat.2021.108476.Peer-Reviewed Original ResearchConceptsSubstance use disordersChronic diseasesIntegrated Promoting ActionHealth Services frameworkHealth care providersSubstance use treatmentPositive longitudinal relationshipPromoting ActionCare providersUse disordersUse treatmentSubstance useSemi-structured interviewsLead professionalsProcedural complexityLongitudinal relationshipDiseaseResearch implementationOngoing trainingProgram implementationDiversionNew HavenLead programFacilitatorsQualitative evaluation
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskPharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
Joudrey PJ, Chadi N, Roy P, Morford KL, Bach P, Kimmel S, Wang EA, Calcaterra SL. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study. Drug And Alcohol Dependence 2020, 211: 107968. PMID: 32268248, PMCID: PMC7529685, DOI: 10.1016/j.drugalcdep.2020.107968.Peer-Reviewed Original ResearchOpioid treatment programsMethadone accessOpioid use disorderCross-sectional studyOpioid overdose deathsCensus tractsDrive timeRural census tractsMethadone treatmentOverdose deathsUse disordersLong drive timesMethadoneTreatment programChain pharmaciesTractMedian differenceRural censusHigh ratePharmacyMedianUnited StatesPopulation
2019
Treatment of Opioid Use Disorder in the Acute Hospital Setting: a Critical Review of the Literature (2014–2019)
Weimer M, Morford K, Donroe J. Treatment of Opioid Use Disorder in the Acute Hospital Setting: a Critical Review of the Literature (2014–2019). Current Addiction Reports 2019, 6: 339-354. DOI: 10.1007/s40429-019-00267-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsOpioid use disorderAddiction medicine consult serviceHospitalized patientsUse disordersInitiation of MOUDPurpose of ReviewPatientsConcomitant medical conditionsAcute hospital settingHealth care utilizationIntravenous opioid useTreatment of patientsAcute care hospitalsHealth care outcomesHospital initiationRecent FindingsManagementInfectious complicationsOpioid withdrawalOpioid useCare hospitalCare utilizationOutpatient settingPatient outcomesConsult serviceHospital careCare modelMethadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction
Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. Journal Of General Internal Medicine 2019, 34: 1039-1042. PMID: 30729416, PMCID: PMC6544670, DOI: 10.1007/s11606-018-4801-3.Commentaries, Editorials and LettersConceptsOpioid use disorderLife-saving medicationsUse disordersOpioid use disorder treatmentIllicit opioid useUse of medicationsPharmacy-based modelsUse disorder treatmentOpioid useMethadone therapyOpioid epidemicOpioid overdoseOpioid addictionMedicationsMethadoneDisorder treatmentDisordersLogistical barriersTreatmentMajority of peopleMortalityMorbidityBuprenorphineLack accessOverdose